JP2009286804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009286804A5 JP2009286804A5 JP2009212564A JP2009212564A JP2009286804A5 JP 2009286804 A5 JP2009286804 A5 JP 2009286804A5 JP 2009212564 A JP2009212564 A JP 2009212564A JP 2009212564 A JP2009212564 A JP 2009212564A JP 2009286804 A5 JP2009286804 A5 JP 2009286804A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- protein
- follistatin
- muscular dystrophy
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- 102000016970 Follistatin Human genes 0.000 claims 18
- 108010014612 Follistatin Proteins 0.000 claims 18
- 102000004169 proteins and genes Human genes 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 230000004048 modification Effects 0.000 claims 7
- 238000012986 modification Methods 0.000 claims 7
- 102000019203 Follistatin-Related Proteins Human genes 0.000 claims 6
- 108010012820 Follistatin-Related Proteins Proteins 0.000 claims 6
- 208000021642 Muscular disease Diseases 0.000 claims 6
- 208000030159 metabolic disease Diseases 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 201000006938 muscular dystrophy Diseases 0.000 claims 4
- 206010028289 Muscle atrophy Diseases 0.000 claims 3
- 208000016097 disease of metabolism Diseases 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102000004472 Myostatin Human genes 0.000 claims 2
- 108010056852 Myostatin Proteins 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000020763 muscle atrophy Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000035810 Denervation atrophy Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 208000001441 Familial Periodic Paralyses Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010028424 Myasthenic syndrome Diseases 0.000 claims 1
- 206010028629 Myoglobinuria Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000010316 Myotonia congenita Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 201000006793 Walker-Warburg syndrome Diseases 0.000 claims 1
- 210000001766 X chromosome Anatomy 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical group 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000011474 congenital myopathy Diseases 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000009338 distal myopathy Diseases 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 206010016208 familial periodic paralysis Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 206010030875 ophthalmoplegia Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35784602P | 2002-02-21 | 2002-02-21 | |
| US43464502P | 2002-12-20 | 2002-12-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571402A Division JP4429728B2 (ja) | 2002-02-21 | 2003-02-21 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009286804A JP2009286804A (ja) | 2009-12-10 |
| JP2009286804A5 true JP2009286804A5 (2) | 2010-10-21 |
Family
ID=27767537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571402A Expired - Fee Related JP4429728B2 (ja) | 2002-02-21 | 2003-02-21 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
| JP2009212564A Pending JP2009286804A (ja) | 2002-02-21 | 2009-09-14 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571402A Expired - Fee Related JP4429728B2 (ja) | 2002-02-21 | 2003-02-21 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7572763B2 (2) |
| EP (1) | EP1572934A4 (2) |
| JP (2) | JP4429728B2 (2) |
| KR (1) | KR20040096592A (2) |
| AU (1) | AU2003216345A1 (2) |
| BR (1) | BR0307871A (2) |
| CA (1) | CA2476654A1 (2) |
| MX (1) | MXPA04008149A (2) |
| NO (1) | NO20043564L (2) |
| PL (1) | PL374966A1 (2) |
| WO (1) | WO2003072714A2 (2) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| EP1572909A4 (en) * | 2002-02-21 | 2007-06-06 | Wyeth Corp | PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN |
| BR0307871A (pt) | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| MXPA05002968A (es) * | 2002-09-16 | 2005-09-08 | Univ Johns Hopkins | Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina. |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| WO2004064785A2 (en) * | 2003-01-14 | 2004-08-05 | Dana Farber Cancer Institute | Cancer therapy sensitizer |
| RU2322261C2 (ru) * | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| EP1644406B1 (en) * | 2003-07-11 | 2012-08-15 | DeveloGen Aktiengesellschaft | Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| EP3006039B1 (en) | 2004-03-02 | 2021-01-06 | Acceleron Pharma Inc. | Alk7 polypeptides for use in promoting fat loss |
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
| JP2008500373A (ja) * | 2004-05-27 | 2008-01-10 | アクセルロン ファーマ インコーポレーテッド | ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用 |
| AU2005272646A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| JP2008537777A (ja) * | 2005-03-23 | 2008-09-25 | ワイス | Ｇｄｆ−８調節剤に対する免疫応答の検出 |
| EP1864138A2 (en) * | 2005-03-23 | 2007-12-12 | Wyeth | Detection of gdf-8 modulating agents |
| PL2407486T3 (pl) | 2005-08-19 | 2018-05-30 | Wyeth Llc | Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| RU2008136657A (ru) * | 2006-03-28 | 2010-05-10 | Вайет (Us) | Модуляторы gdf-9/bmp-15 для лечения заболеваний костей |
| CA2671983A1 (en) | 2006-12-08 | 2009-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
| US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| CN102131822A (zh) | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| JP2013535981A (ja) | 2010-08-20 | 2013-09-19 | ワイス・エルエルシー | 成長因子不含適合細胞の細胞培養 |
| RU2663794C2 (ru) | 2011-10-21 | 2018-08-09 | Пфайзер Инк. | Добавление железа для улучшения культивирования клеток |
| US20180193306A1 (en) | 2012-03-23 | 2018-07-12 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders and bone disorders |
| KR101704893B1 (ko) | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도 |
| US9873739B2 (en) | 2012-08-01 | 2018-01-23 | Ikaika Therapeutics, Llc | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4) |
| CN104968801B (zh) * | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
| HK1214504A1 (zh) | 2012-10-24 | 2016-07-29 | 细胞基因公司 | 用於治療貧血的方法 |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| ES2715710T3 (es) | 2013-01-25 | 2019-06-05 | Shire Human Genetic Therapies | Folistatina en el tratamiento de la distrofía muscular de Duchenne |
| JP2014151438A (ja) * | 2013-02-04 | 2014-08-25 | Koito Mfg Co Ltd | レーザー溶着方法 |
| GB201308117D0 (en) * | 2013-05-06 | 2013-06-12 | Univ Leuven Kath | Inhibitor of calcifying disorders |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| EA202090632A1 (ru) | 2014-06-04 | 2020-07-31 | Акселерон Фарма Инк. | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов |
| EP3274457A4 (en) | 2015-03-26 | 2018-08-08 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| MA45811A (fr) | 2016-07-27 | 2019-06-05 | Acceleron Pharma Inc | Méthodes et compositions de traitement de maladie. |
| WO2018218273A1 (en) * | 2017-05-29 | 2018-12-06 | Paranta Biosciences Limited | Method of treating hypertension and kidney disease |
| KR101822633B1 (ko) * | 2017-08-22 | 2018-01-26 | (주)진셀팜 | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 |
| JP2021514380A (ja) * | 2018-02-20 | 2021-06-10 | エピリウム バイオ インコーポレイテッド | 筋障害を処置するための化合物及び組成物 |
| WO2020132647A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| MX2019015589A (es) * | 2019-12-19 | 2021-06-21 | Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C | Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular. |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5116944A (en) | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
| US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US6673534B1 (en) * | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| US6607884B1 (en) * | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| DK0690873T3 (da) * | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| WO1994026892A1 (en) * | 1993-05-12 | 1994-11-24 | Genetics Institute, Inc. | Bmp-11 compositions |
| EP1716864A1 (en) * | 1993-08-26 | 2006-11-02 | Genetics Institute, LLC | Neural regeneration using home bone morphogenetic proteins |
| US7332575B2 (en) * | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| EP1574577A3 (en) | 1994-07-08 | 2006-06-14 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
| US6548644B1 (en) * | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| JP2001513982A (ja) * | 1997-08-29 | 2001-09-11 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | フォリスタチン−３ |
| WO1999024057A2 (en) | 1997-11-07 | 1999-05-20 | Genetics Inst | Neuronal uses of bmp-11 |
| US5942420A (en) | 1997-11-17 | 1999-08-24 | Millennium Biotherapeutics, Inc. | Molecules of the follistatin-related protein family and uses therefor |
| US6369201B1 (en) * | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| JP4544742B2 (ja) | 1998-05-06 | 2010-09-15 | メタモーフイクス・インコーポレーテツド | Ｇｄｆ−８の阻害による糖尿病の処置法 |
| EP1105477A1 (en) | 1998-08-20 | 2001-06-13 | Regeneron Pharmaceuticals, Inc. | Dcr5, a bmp-binding protein, and applications thereof |
| AU6289999A (en) * | 1998-10-15 | 2000-05-01 | Zymogenetics Inc. | Follistatin-related protein zfsta2 |
| MXPA01007366A (es) | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
| AU6098300A (en) | 1999-07-16 | 2001-02-05 | Human Genome Sciences, Inc. | Follistatin-3 |
| US7098372B1 (en) * | 1999-09-13 | 2006-08-29 | Wyeth | Pharmaceutical compositions and methods of using secreted frizzled related protein |
| EP1226249A2 (en) * | 1999-11-03 | 2002-07-31 | ZymoGenetics, Inc. | Follistatin-related protein zfsta4 |
| WO2001064888A2 (en) | 2000-02-29 | 2001-09-07 | Zymogenetics, Inc. | Kunitz domain polypeptide zkun8 |
| JP2003525634A (ja) * | 2000-03-03 | 2003-09-02 | キュラジェン コーポレイション | Ｆｃｔｒｘと命名されたタンパク質およびこれをコードする核酸 |
| EP2213743A1 (en) * | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| EP1572909A4 (en) * | 2002-02-21 | 2007-06-06 | Wyeth Corp | PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN |
| BR0307871A (pt) | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| MXPA05002968A (es) | 2002-09-16 | 2005-09-08 | Univ Johns Hopkins | Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina. |
| AR047392A1 (es) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| BR0317538A (pt) | 2002-12-20 | 2005-11-29 | Amgen Inc | Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo |
| EP1864138A2 (en) * | 2005-03-23 | 2007-12-12 | Wyeth | Detection of gdf-8 modulating agents |
| JP2008537777A (ja) * | 2005-03-23 | 2008-09-25 | ワイス | Ｇｄｆ−８調節剤に対する免疫応答の検出 |
-
2003
- 2003-02-21 BR BR0307871-0A patent/BR0307871A/pt not_active IP Right Cessation
- 2003-02-21 CA CA002476654A patent/CA2476654A1/en not_active Abandoned
- 2003-02-21 MX MXPA04008149A patent/MXPA04008149A/es active IP Right Grant
- 2003-02-21 KR KR10-2004-7012978A patent/KR20040096592A/ko not_active Withdrawn
- 2003-02-21 US US10/369,738 patent/US7572763B2/en not_active Expired - Fee Related
- 2003-02-21 EP EP03743174A patent/EP1572934A4/en not_active Withdrawn
- 2003-02-21 PL PL03374966A patent/PL374966A1/xx not_active Application Discontinuation
- 2003-02-21 AU AU2003216345A patent/AU2003216345A1/en not_active Withdrawn
- 2003-02-21 WO PCT/US2003/005150 patent/WO2003072714A2/en not_active Ceased
- 2003-02-21 JP JP2003571402A patent/JP4429728B2/ja not_active Expired - Fee Related
-
2004
- 2004-08-26 NO NO20043564A patent/NO20043564L/no not_active Application Discontinuation
-
2009
- 2009-06-02 US US12/476,489 patent/US20100047259A1/en not_active Abandoned
- 2009-09-14 JP JP2009212564A patent/JP2009286804A/ja active Pending
-
2010
- 2010-09-17 US US12/884,371 patent/US20110020372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009286804A5 (2) | ||
| JP2005531505A5 (2) | ||
| JP2005534616A5 (2) | ||
| JP2010031018A5 (2) | ||
| TWI793069B (zh) | 升糖素及ｇｌｐ－１共促效劑於治療肥胖之用途 | |
| US20130137629A1 (en) | Combination treatment for metabolic disorders | |
| JP2011506442A5 (2) | ||
| CA3237751A1 (en) | Ionic liquid compositions | |
| JP2011500850A5 (2) | ||
| JP2006501820A5 (2) | ||
| JP2012525844A5 (2) | ||
| JP2015517459A5 (2) | ||
| JP2007500236A5 (2) | ||
| RU2011117645A (ru) | Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день | |
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| JP2012520866A5 (2) | ||
| TW201206469A (en) | Novel antibody formulation | |
| WO2009139362A1 (ja) | Dpp-iv阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬 | |
| JP2022504153A5 (2) | ||
| CN103665148A (zh) | 一种可口服给药的降糖多肽及其制法和用途 | |
| CA2678646A1 (en) | A conjugate of insulin and vitamin b12 for oral delivery | |
| JP2009519949A5 (2) | ||
| TW202133882A (zh) | 肽與多醣的新共軛物 | |
| JP2016526533A (ja) | アミリンミメティック化合物とポリエチレングリコールの非凝集バイオ接合体 | |
| JP2023116456A (ja) | 強皮症関連血管障害を治療または改善するための組成物および方法 |